Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice

Psychiatric Clinics of North America

Volumn 39, Issue 3, 2016, Pages 391-411

  Caroff, Stanley N ^a   Campbell, E Cabrina ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Akathisia; Antipsychotic drugs; Catatonia; Dystonia; Neuroleptic malignant syndrome; Parkinsonism; Schizophrenia; Tardive dyskinesia

Indexed keywords

AMANTADINE; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DANTROLENE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; MEMANTINE; MIRTAZAPINE; MUSCARINIC AGENT; NEUROLEPTIC AGENT; NICOTINIC AGENT; PERPHENAZINE; PLACEBO; PROPRANOLOL; QUETIAPINE; SEROTONIN 2A ANTAGONIST; TETRABENAZINE;

AKATHISIA; BRADYCARDIA; CATATONIA; CHEMOPROPHYLAXIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYNDROME; HIGH RISK POPULATION; HUMAN; HYPOTENSION; INCIDENCE; LOW DRUG DOSE; MOTOR SYSTEM; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; OFF LABEL DRUG USE; PARKINSONISM; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SINGLE DRUG DOSE; TARDIVE DYSKINESIA; DYSKINESIA, DRUG-INDUCED;

ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS;

EID: 84991269945     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2016.04.003     Document Type: Review

References (128)

1. 1 Owens, D.G.C., A guide to the extrapyramidal side-effects of antipsychotic drugs. 2nd edition, 2014, Cambridge University Press, Cambridge (United Kingdom).
2. 2 Van Putten, T., Why do schizophrenic patients refuse to take their drugs?. Arch Gen Psychiatry 31 (1975), 67–72.
3. 3 Rifkin, A., Extrapyramidal side effects: a historical perspective. J Clin Psychiatry 48:Suppl (1987), 3–6.
4. 4 Caroff, S., The neuroleptic malignant syndrome. J Clin Psychiatry 41 (1980), 79–83.
5. 5 Kane, J., Honigfeld, G., Singer, J., et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:9 (1988), 789–796.
6. 6 Arvanitis, L.A., Miller, B.G., Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42:4 (1997), 233–246.
7. 7 Potkin, S.G., Saha, A.R., Kujawa, M.J., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:7 (2003), 681–690.
8. 8 Tollefson, G.D., Beasley, C.M. Jr., Tran, P.V., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:4 (1997), 457–465.
9. 9 Marder, S.R., Meibach, R.C., Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:6 (1994), 825–835.
10. 10 Daniel, D.G., Zimbroff, D.L., Potkin, S.G., et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:5 (1999), 491–505.
11. 11 Dossenbach, M., Arango-Davila, C., Silva Ibarra, H., et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study. J Clin Psychiatry 66:8 (2005), 1021–1030.
12. 12 Correll, C.U., Leucht, S., Kane, J.M., Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:3 (2004), 414–425.
13. 13 Tenback, D.E., van Harten, P.N., Slooff, C.J., et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European schizophrenia outpatient health outcomes (SOHO) study. J Clin Psychiatry 66:9 (2005), 1130–1133.
14. 14 Caroff, S.N., Mann, S.C., Campbell, E.C., et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 63:Suppl 4 (2002), 12–19.
15. 15 Tarsy, D., Baldessarini, R.J., Tarazi, F.I., Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16:1 (2002), 23–45.
16. 16 Kane, J.M., Woerner, M., Lieberman, J., Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 8:4 Suppl (1988), 52S–56S.
17. 17 Glazer, W.M., Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 61:Suppl 4 (2000), 21–26.
18. 18 Glazer, W.M., Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 61:Suppl 3 (2000), 16–21.
19. 19 Leucht, S., Pitschel-Walz, G., Abraham, D., et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:1 (1999), 51–68.
20. 20 Meltzer, H.Y., The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:2 (1991), 263–287.
21. 21 Davis, J.M., Chen, N., Glick, I.D., A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:6 (2003), 553–564.
22. 22 Geddes, J., Freemantle, N., Harrison, P., et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:7273 (2000), 1371–1376.
23. 23 Leucht, S., Wahlbeck, K., Hamann, J., et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:9369 (2003), 1581–1589.
24. 24 Rosenheck, R., Perlick, D., Bingham, S., et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:20 (2003), 2693–2702.
25. 25 Hugenholtz, G.W., Heerdink, E.R., Stolker, J.J., et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry 67:6 (2006), 897–903.
26. 26 Jones, P.B., Barnes, T.R., Davies, L., et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:10 (2006), 1079–1087.
27. 27 Correll, C.U., Schenk, E.M., Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21:2 (2008), 151–156.
28. 28 Lieberman, J.A., Stroup, T.S., McEvoy, J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:12 (2005), 1209–1223.
29. 29 Miller, D.D., Caroff, S.N., Davis, S.M., et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 193:4 (2008), 279–288.
30. 30 Caroff, S.N., Miller, D.D., Rosenheck, R.A., Extrapyramidal side effects. Stroup, T.S., Lieberman, J.A., (eds.) The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: how does it inform practice, policy, and research?, 2010, Cambridge University Press, Cambridge (United Kingdom), 156–172.
31. 31 Tarsy, D., Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 6:Suppl 1 (1983), S9–S26.
32. 32 Caroff, S.N., Hurford, I., Lybrand, J., et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 29:1 (2011), 127–148.
33. 33 Satterthwaite, T.D., Wolf, D.H., Rosenheck, R.A., et al. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 69:12 (2008), 1869–1879.
34. 34 Tarsy, D., Simon, D.K., Dystonia. N Engl J Med 355:8 (2006), 818–829.
35. 35 van Harten, P.N., Hoek, H.W., Kahn, R.S., Acute dystonia induced by drug treatment. BMJ 319:7210 (1999), 623–626.
36. 36 Rupniak, N.M., Jenner, P., Marsden, C.D., Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 88:4 (1986), 403–419.
37. 37 Marsden, C.D., Quinn, N.P., The dystonias. BMJ 300:6718 (1990), 139–144.
38. 38 Nemeth, A.H., The genetics of primary dystonias and related disorders. Brain 125:Pt 4 (2002), 695–721.
39. 39 Keepers, G.A., Casey, D.E., Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 7:5 (1987), 342–345.
40. 40 Crisafulli, C., Drago, A., Sidoti, A., et al. A genetic dissection of antipsychotic induced movement disorders. Curr Med Chem 20:3 (2013), 312–330.
41. 41 Keepers, G.A., Clappison, V.J., Casey, D.E., Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:10 (1983), 1113–1117.
42. 42 Simpson, G.M., Lindenmayer, J.P., Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 17:3 (1997), 194–201.
43. 43 Arana, G.W., Goff, D.C., Baldessarini, R.J., et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 145:8 (1988), 993–996.
44. 44 Dayalu, P., Chou, K.L., Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 9:9 (2008), 1451–1462.
45. 45 Berardelli, A., Rothwell, J.C., Hallett, M., et al. The pathophysiology of primary dystonia. Brain 121:Pt 7 (1998), 1195–1212.
46. 46 Thanvi, B., Treadwell, S., Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 85:1004 (2009), 322–326.
47. 47 Bovi, T., Antonini, A., Ottaviani, S., et al. The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. J Neurol 257:11 (2010), 1882–1889.
48. 48 Morley, J.F., Duda, J.E., Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease. J Parkinsons Dis 4:2 (2014), 169–173.
49. 49 Morley, J.F., Pawlowski, S.M., Kesari, A., et al. Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism. Parkinsonism Relat Disord 20:7 (2014), 738–742.
50. 50 Gelenberg, A.J., General principles of treatment of extrapyramidal syndromes. Clin Neuropharmacol 6:Suppl 1 (1983), S52–S56.
51. 51 Bras, J.M., Singleton, A., Genetic susceptibility in Parkinson's disease. Biochim Biophys Acta 1792:7 (2009), 597–603.
52. 52 Snyder, S., Greenberg, D., Yamamura, H.I., Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 31:1 (1974), 58–61.
53. 53 Hirsch, S.R., Kissling, W., Bauml, J., et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 63:6 (2002), 516–523.
54. 54 Barnes, T.R., McPhillips, M.A., Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry Suppl 38 (1999), 34–43.
55. 55 McKeith, I.G., Dickson, D.W., Lowe, J., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65:12 (2005), 1863–1872.
56. 56 Gelenberg, A.J., Treating extrapyramidal reactions: some current issues. J Clin Psychiatry 48:Suppl (1987), 24–27.
57. 57 Kane, J.M., Fleischhacker, W.W., Hansen, L., et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 70:5 (2009), 627–643.
58. 58 Bratti, I.M., Kane, J.M., Marder, S.R., Chronic restlessness with antipsychotics. Am J Psychiatry 164:11 (2007), 1648–1654.
59. 59 Poyurovsky, M., Acute antipsychotic-induced akathisia revisited. Br J Psychiatry 196:2 (2010), 89–91.
60. 60 Sachdev, P., Kruk, J., Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 51:12 (1994), 963–974.
61. 61 Eichhammer, P., Albus, M., Borrmann-Hassenbach, M., et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet 96:2 (2000), 187–191.
62. 62 Pichler, I., Hicks, A.A., Pramstaller, P.P., Restless legs syndrome: an update on genetics and future perspectives. Clin Genet 73:4 (2008), 297–305.
63. 63 Miller, C.H., Fleischhacker, W.W., Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 22:1 (2000), 73–81.
64. 64 Rathbone, J., Soares-Weiser, K., Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev(4), 2006 CD003727.
65. 65 Ungvari, G.S., Caroff, S.N., Gerevich, J., The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophr Bull 36:2 (2010), 231–238.
66. 66 Ungvari, G.S., Catatonia in DSM 5: controversies regarding its psychopathology, clinical presentation and treatment response. Neuropsychopharmacol Hung 16:4 (2014), 189–194.
67. 67 Lopez-Canino, A., Francis, A., Drug-induced catatonia. Caroff, S.N., Mann, S.C., Francis, A., et al. (eds.) Catatonia: from psychopathology to neurobiology, 2004, American Psychiatric Press, Inc., Washington, DC, 129–139.
68. 68 Gelenberg, A.J., Mandel, M.R., Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatry 34:8 (1977), 947–950.
69. 69 White, D.A., Robins, A.H., An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome. CNS Spectr 5:7 (2000), 58–65.
70. 70 Mann, S.C., Caroff, S.N., Bleier, H.R., et al. Lethal catatonia. Am J Psychiatry 143:11 (1986), 1374–1381.
71. 71 Gelenberg, A.J., The catatonic syndrome. Lancet 1:7973 (1976), 1339–1341.
72. 72 Caroff, S.N., Hurford, I., Bleier, H.R., et al. Recurrent idiopathic catatonia: implications beyond the diagnostic and statistical manual of mental disorders 5th edition. Clin Psychopharmacol Neurosci 13:2 (2015), 218–221.
73. 73 Brenner, I., Rheuban, W.J., The catatonic dilemma. Am J Psychiatry 135:10 (1978), 1242–1243.
74. 74 Stubner, S., Rustenbeck, E., Grohmann, R., et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37:Suppl 1 (2004), S54–S64.
75. 75 Van Den Eede, F., Van Hecke, J., Van Dalfsen, A., et al. The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry 20:5–6 (2005), 422–429.
76. 76 Peralta, V., Campos, M.S., de Jalon, E.G., et al. DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr Res 118:1–3 (2010), 168–175.
77. 77 Carroll, B.T., Goforth, H.W., Thomas, C., et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 19:4 (2007), 406–412.
78. 78 Mann, S.C., Caroff, S.N., Fricchione, G., et al. Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann 30 (2000), 363–374.
79. 79 Stober, G., Genetics. Caroff, S.N., Mann, S.C., Francis, A., et al. (eds.) Catatonia: from psychopathology to neurobiology, 2004, American Psychiatric Press, Inc, Washington, DC, 173–187.
80. 80 Ehrenreich, H., Nave, K.A., Phenotype-based genetic association studies (PGAS)-towards understanding the contribution of common genetic variants to schizophrenia subphenotypes. Genes (Basel) 5:1 (2014), 97–105.
81. 81 Kanes, S.J., Animal models. Caroff, S.N., Mann, S.C., Francis, A., et al. (eds.) Catatonia: from psychopathology to neurobiology, 2004, American Psychiatric Press, Inc., Washington, DC, 189–200.
82. 82 Caroff, S.N., Mann, S.C., Neuroleptic malignant syndrome. Med Clin North Am 77:1 (1993), 185–202.
83. 83 Strawn, J.R., Keck, P.E. Jr., Caroff, S.N., Neuroleptic malignant syndrome. Am J Psychiatry 164:6 (2007), 870–876.
84. 84 Caroff, S.N., Mann, S.C., Campbell, E.C., et al. Severe drug reactions. Ferrando, S.J., Levenson, J.L., Owen, J.A., (eds.) Clinical manual of psychopharmacology in the medically III, 2010, American Psychiatric Press, Inc., Washington, DC, 39–77.
85. 85 Gurrera, R.J., Caroff, S.N., Cohen, A., et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72:9 (2011), 1222–1228.
86. 86 Caroff, S.N., Mann, S.C., McCarthy, M., et al. Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol 18:4 (1998), 349–351.
87. 87 Caroff, S.N., Campbell, E.C., Risk of neuroleptic malignant syndrome in patients with NMDAR encephalitis. Neurol Sci 36:3 (2015), 479–480.
88. 88 Mann, S.C., Boger, W.P., Psychotropic drugs, summer heat and humidity, and hyperpyrexia: a danger restated. Am J Psychiatry 135:9 (1978), 1097–1100.
89. 89 Caroff, S.N., Rosenberg, H., Mann, S.C., et al. Neuroleptic malignant syndrome in the perioperative setting. Am J Anesthesiol 28 (2001), 387–393.
90. 90 Caroff, S.N., Mann, S.C., Keck, P.E. Jr., et al. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 20:2 (2000), 257–259.
91. 91 Modi, S., Dharaiya, D., Schultz, L., et al. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care 24:1 (2016), 97–103.
92. 92 Stevens, D.L., Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 42:9 (2008), 1290–1297.
93. 93 Gurrera, R.J., Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 156:2 (1999), 169–180.
94. 94 Kane, J.M., Tardive dyskinesia: epidemiological and clinical presentation. Bloom, F.E., Kupfer, D.J., (eds.) Psychopharmacology: the fourth generation of progress, 1995, Raven Press, New York, 1485–1495.
95. 95 Casey, D.E., Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4:2 (1991), 109–120.
96. 96 Caroff, S.N., Davis, V.G., Miller, D.D., et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry 72:3 (2011), 295–303.
97. 97 Adityanjee, Aderibigbe, Y.A., Jampala, V.C., et al. The current status of tardive dystonia. Biol Psychiatry 45:6 (1999), 715–730.
98. 98 Burke, R.E., Kang, U.J., Jankovic, J., et al. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 4:2 (1989), 157–175.
99. 99 Casey, D.E., Gerlach, J., Tardive dyskinesia: what is the long-term outcome?. Casey, D.E., Gardos, G., (eds.) Tardive dyskinesia and neuroleptics: from dogma to reason, 1986, American Psychiatric Press, Inc., Washington, DC, 76–97.
100. 100 Glazer, W.M., Moore, D.C., Schooler, N.R., et al. Tardive dyskinesia. A discontinuation study. Arch Gen Psychiatry 41:6 (1984), 623–627.
101. 101 Glazer, W.M., Morgenstern, H., Schooler, N., et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 157 (1990), 585–592.
102. 102 Soares, K.V., McGrath, J.J., The treatment of tardive dyskinesia–a systematic review and meta-analysis. Schizophr Res 39:1 (1999), 1–16 [discussion: 17–8].
103. 103 Egan, M.F., Apud, J., Wyatt, R.J., Treatment of tardive dyskinesia. Schizophr Bull 23:4 (1997), 583–609.
104. 104 Chakos, M.H., Alvir, J.M., Woerner, M.G., et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 53:4 (1996), 313–319.
105. 105 Oosthuizen, P.P., Emsley, R.A., Maritz, J.S., et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 64:9 (2003), 1075–1080.
106. 106 Jeste, D.V., Tardive dyskinesia in older patients. J Clin Psychiatry 61:Suppl 4 (2000), 27–32.
107. 107 Miller, D.D., McEvoy, J.P., Davis, S.M., et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 80:1 (2005), 33–43.
108. 108 Lv, Z., Rong, B., Tong, X., et al. The association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk. Int J Neurosci, 2015, 1–7.
109. 109 Zai, C.C., Tiwari, A.K., Mazzoco, M., et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res 47:11 (2013), 1760–1765.
110. 110 Tsai, H.T., Caroff, S.N., Miller, D.D., et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 153B:1 (2009), 336–340.
111. 111 Aberg, K., Adkins, D.E., Bukszar, J., et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 67:3 (2010), 279–282.
112. 112 Beasley, C.M., Dellva, M.A., Tamura, R.N., et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 174 (1999), 23–30.
113. 113 Jeste, D.V., Lacro, J.P., Bailey, A., et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 47:6 (1999), 716–719.
114. 114 Kane, J.M., Tardive dyskinesia circa 2006. Am J Psychiatry 163:8 (2006), 1316–1318.
115. 115 Kane, J.M., Woerner, M.G., Pollack, S., et al. Does clozapine cause tardive dyskinesia?. J Clin Psychiatry 54:9 (1993), 327–330.
116. 116 Lieberman, J.A., Saltz, B.L., Johns, C.A., et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158 (1991), 503–510.
117. 117 Jeste, D.V., Lohr, J.B., Clark, K., et al. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 8:4 Suppl (1988), 38S–48S.
118. 118 Bhidayasiri, R., Fahn, S., Weiner, W.J., et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 81:5 (2013), 463–469.
119. 119 Lockwood, J.T., Remington, G., Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in phase II and phase III clinical trials. Expert Opin Emerg Drugs 20:3 (2015), 407–421.
120. 120 Jankovic, J., Clarence-Smith, K., Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 11:11 (2011), 1509–1523.
121. 121 O'Brien, C.F., Jimenez, R., Hauser, R.A., et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord 30:12 (2015), 1681–1687.
122. 122 Pappa, S., Tsouli, S., Apostolou, G., et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 33:6 (2010), 271–275.
123. 123 Miller, R., Chouinard, G., Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 34:10 (1993), 713–738.
124. 124 Caroff, S.N., Campbell, E.C., Havey, J., et al. Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry 62:10 (2001), 772–775.
125. 125 Caroff, S.N., Walker, P., Campbell, C., et al. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry 68:3 (2007), 410–415.
126. 126 Quik, M., Bordia, T., Zhang, D., et al. Nicotine and nicotinic receptor drugs: potential for Parkinson's disease and drug-induced movement disorders. Int Rev Neurobiol 124 (2015), 247–271.
127. 127 Di Paolo, T., Gregoire, L., Feuerbach, D., et al. AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces L-dopa-induced dyskinesias and extends the duration of L-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord 20:11 (2014), 1119–1123.
128. 128 Shen, W., Plotkin, J.L., Francardo, V., et al. M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-induced dyskinesia. Neuron 88:4 (2015), 762–773.